rHSA vs. HSA vs. BSA
BSA, HSA, and rHSA are all albumins — but they are not interchangeable. The choice determines whether your serum-free medium works, whether your DMPK assay is FDA-compliant, and whether your IVD calibrator is commutable. This guide gives you a clear decision framework. Buy albumin – HSA, rHSA and BSA from EU stock Request a quote […]
Leitfaden Tierseren
Animal sera from species other than cattle serve highly specific roles in research — from blocking non-specific binding in immunofluorescence to providing complement activity for hemolytic assays. Choosing the wrong species or grade wastes time and money. This guide covers when and why to use each species. Buy animal sera from EU stock Request a […]
Protokoll zur Adaptation von HEK293T an serumfreies Medium
HEK293T cells adapt to serum-free medium more readily than most mammalian cell lines — but the adaptation process has one critical failure point that most protocols ignore: the suspension cells that detach during the early adaptation phase. This protocol covers the complete adaptation procedure using SimplaceX and SimplaceCDX, including how to rescue and reintegrate suspension […]
MSC-Expansion – hPL vs. FKS
The evidence base comparing human platelet lysate (hPL) and FBS for mesenchymal stem cell (MSC) expansion has grown substantially over the past decade. The conclusion is remarkably consistent across studies, cell sources, and laboratories: hPL at 5% outperforms FBS at 10% for MSC proliferation rate, and produces MSCs with equivalent or superior immunomodulatory potency. This […]
CAR-T-Zell-Expansion – hPL vs. FKS
The shift from FBS to human platelet lysate (hPL) in CAR-T cell manufacturing is no longer a regulatory preference — it is becoming the de facto standard for clinical-grade production. But the decision is not purely regulatory. There is a growing body of published data showing that hPL-expanded T cells are functionally different from FBS-expanded […]
Verhältnis leerer zu vollen AAV-Kapsiden
A 2025 multi-omics study found that 46% of HEK293T cells in a standard triple transfection AAV production run lacked transcripts from at least one of the three plasmids — meaning nearly half of cells were structurally incapable of producing full, genome-containing AAV particles. This single finding explains most of what we observe as “high empty […]
2D-Bioprocessing-Beutel für AAV-Wirkstoff
AAV drug substance freeze-thaw is one of the most critical unit operations in gene therapy manufacturing — and one of the most underappreciated sources of product loss. The choice of container geometry for freeze-thaw has a direct impact on viral particle recovery, aggregation, and potency. This post explains why 2D flat bags are the standard […]
FKS vs. serumfrei in der AAV-Produktion
The question is not whether serum-free medium is better than FBS for AAV production — in terms of titre, a well-optimised serum-free medium matches FBS. The question is when the regulatory, operational, and quality advantages of serum-free outweigh the adaptation cost. This post gives you a practical decision framework by development phase and intended use. […]
Serumfreies Medium für die AAV-Produktion
Moving AAV production from serum-containing to serum-free medium is increasingly driven by regulatory pressure — particularly for IND-enabling and clinical-grade AAV where animal-derived components require extensive TSE/BSE documentation. This post gives you the complete component list, explains what each component replaces in FBS, and provides a practical transition protocol. Buy serum-free cell culture media from […]
Konfluenz von HEK293T bei der Transfektion
Every AAV production protocol says it: “transfect at 70–80% confluency.” But few explain why this number is so critical — and fewer still explain how to actually measure it reliably at scale. This post covers the cell biology behind the confluency requirement and the practical approaches to monitoring it consistently. Why confluency at transfection determines […]
English
Deutsch